Secondary Logo

Journal Logo

HEMATOPOIESIS: Edited by Hal E. Broxmeyer

Fight or flight

regulation of emergency hematopoiesis by pyroptosis and necroptosis

Croker, Ben A.a; Silke, Johnb,c; Gerlic, Mottid

Author Information
Current Opinion in Hematology: July 2015 - Volume 22 - Issue 4 - p 293-301
doi: 10.1097/MOH.0000000000000148
  • Free

Abstract

INTRODUCTION

In the battle of microbes and mammalian cells, the fight or flight (die) decision is emerging as a central factor contributing to resistance to infection. Since the work of Bradley and Metcalf in the 1960s on colony-stimulating factors that regulate hematopoiesis [1,2], we have gained a deep understanding of soluble factors and downstream signaling pathways controlling hematopoiesis at steady state and following infection. Changes in the induction of inflammatory cytokines and hematopoietic growth factors in response to microbes have been intensively studied as a mechanism to explain abnormal responses to infection and the development of immune suppression. Despite this effort, few immunological studies explain the common occurrence of multilineage suppression of hematopoiesis in patients with life-threatening systemic infections.

A hematological hallmark of septic shock patients is peripheral blood cytopenia [3]. This persistent cytopenia commonly affects myeloid, lymphoid, and erythroid lineages, resulting in immunosuppression, and is a key prognostic indicator for survival. The Pediatric Acute Lung Injury and Sepsis Investigators network revealed that nonsurvivors of ‘influenza’ infection appear to have defective emergency hematopoiesis and were therefore profoundly pancytopenic and had frequently developed a bacterial superinfection [4]. However, a convincing mechanism to explain this failure of emergency hematopoiesis has not been proposed. Numerous viral and bacterial pathogens, including HIV, lymphocytic choriomeningitis virus, cytomegalovirus, human herpesvirus-6, human herpesvirus-7, vaccinia virus (VACV), Bartonella, and parvovirus B19, are known to infect hematopoietic stem progenitor cells (HSPCs) and in some cases, remain dormant in HSPCs [5–12]. Recently, it was revealed that abortive HIV infection of T cells induces a caspase-1-dependent cell death, known as pyroptosis [13,14]. HIV infection can infect hematopoietic progenitor cells and induce cytopenia, and numerous studies demonstrate that infection of CD34+ HSPCs with HIV induces cell death and impairs reconstitution in humanized mouse models [6,11,15–17].

One possibility to explain defects in emergency hematopoiesis during systemic infection is the inappropriate activation of cell death, a hypothesis proposed by Hotchkiss et al.[18,19] in 1999 using data collected from mice and humans. Alternatively, suppression of HSPC proliferation, differentiation, and self-renewal can also explain these clinical syndromes. Recent findings demonstrate that hematopoietic progenitor cells drive hematopoiesis at steady state, rather than long-term hematopoietic stem cells (HSC), suggesting that the response of the progenitor cell compartment to intracellular infection and inflammatory cytokines may be central to an effective immune response [20▪,21▪].

Since 1972, apoptotic and necrotic cell death has dominated the literature as two forms of cell death with distinct effects on the immune system [22]. The discovery of genes regulating apoptosis, most notably B-cell lymphoma 2 (Bcl-2) [23], has driven major scientific and clinical advances in the field of cell death. Alternative nonapoptotic modes of programmed cell death have been recently recognized to exist, including pyroptosis – a caspase-1-dependent cell death – and necroptosis – a receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like protein (MLKL)-dependent, caspase-independent cell death (Fig. 1).

FIGURE 1
FIGURE 1:
Apoptosis and the inflammatory cell death pathways, pyroptosis, and necroptosis. Nonapoptotic cell death pathways can be triggered by numerous factors including inflammasome activation, death receptor ligation, and intracellular pathogens. When caspase activity is blocked, TLR ligation and a cytoplasmic complex comprising RIPK1 can drive necroptotic death. Phosphorylation and oligomerization of RIPK3 activates necroptosis by inducing phosphorylation of MLKL and its translocation to cell membranes. The cellular contents released from necroptotic cells can serve as DAMPs to further induce inflammation. Pyroptosis is induced by the formation of the inflammasome complex to induce caspase-1 activation and IL-1β and IL-18 maturation. Pathogen clearance and inflammation must be balanced to prevent a chronic inflammatory response. DAMP, damage-associated molecular pattern; IL, interleukin; MLKL, mixed lineage kinase domain-like protein; RIPK, receptor-interacting protein kinase; TLR, Toll-like receptor.

There are a multitude of intracellular proteins acting as cellular sentinels that monitor for signs of infection. When triggered, they move swiftly to induce the release of inflammatory cytokines and/or to induce an inflammatory form of cell death, both of which can drive emergency hematopoiesis. During pyroptosis or necroptosis, emergency hematopoiesis can be potently influenced by the programmed release of inflammatory cytokines. The release of host-derived damage-associated molecular patterns (DAMPs) such as mitochondrial DNA [24] and high-mobility group protein B1 (HMGB1) [25] further induces cytokine production and influences emergency hematopoiesis [26▪▪,27] (Fig. 2). These forms of cell death contrast to the immunologically-silent apoptotic forms of cell death [28]. How cells choose the fight or die option during infection remains enigmatic: is it a binary switch controlling both cytokine production and nonapoptotic cell death? Or does this depend on the cell type and the pathway recruited? What are the crucial intracellular targets of these cell death pathways that culminate in the demise of the cell? And what are the specific DAMPs that activate the surrounding immune cells to drive inflammation and emergency hematopoiesis? Here, we will focus on the role of inflammatory cell death including pyroptosis and necroptosis as key mechanisms controlling emergency hematopoiesis. We will discuss recent advances which demonstrate that nonapoptotic inflammatory cell death can regulate emergency hematopoiesis.

FIGURE 2
FIGURE 2:
Direct and indirect effects of pyroptosis and necroptosis on emergency hematopoiesis. The nonapoptotic and inflammatory forms of cell death, pyroptosis, and necroptosis have direct and indirect effects on emergency hematopoiesis. These modalities of cell death release inflammatory cytokines and DAMPs that stimulate emergency hematopoiesis. In chronic settings, including prolonged periods of infectious stress that may be characterized by secondary infection or systemic infection, these inflammatory factors may impair hematopoiesis. Pyroptosis and necroptosis can also exert a strong influence on hematopoiesis by directly killing HSPCs. DAMP, damage-associated molecular pattern; HSPC, hematopoietic stem and progenitor cell.
Box 1
Box 1:
no caption available

DEFINING THE FORMS OF INFLAMMATORY CELL DEATH

The Nomenclature Committee on Cell Death has prepared guidelines to define different forms of cell death, including intrinsic and extrinsic apoptosis, mitotic catastrophe, and necroptosis [29▪]. Here, we will extend the definitions of pyroptosis to include recent data and to acknowledge the significant differences in morphology of pyroptotic cells [30].

The dependence on RIPK3 and the pseudo-kinase MLKL provides the best definition of necroptosis [31]. The common use of necrostatin-1 (Nec-1) and necrostatin-1s – chemical inhibitors of RIPK1 – to define necroptotic death can be useful; however, RIPK1-independent, RIPK3-dependent forms of death are now well recognized [32▪▪–34▪▪]. Furthermore Nec-1 may inhibit inflammatory cell responses that are not linked to cell death [35,36▪▪]. Like apoptosis, where a multitude of inputs and cellular stresses can trigger the apoptotic cascade, necroptosis can be engaged via numerous upstream pathways. These include the ligation of death receptors, Toll-like receptors (TLRs), and intracellular receptors such as DNA-dependent activator of interferon-regulatory factors (DAI) [37–39] (Fig. 1). Negative regulators are also now well defined: RIPK1, caspase-8, cellular FADD-like IL-1β-converting enzyme-inhibitory protein (cFLIP), and Fas-associated protein with Death Domain (FADD) all play key roles in restricting the activity of the necroptotic pathway [32▪▪–34▪▪,40,41▪,42,43]. Combined, these upstream regulators form an important arm of the innate immune system, acting as sentinels for pathogens or other pathophysiological processes that aim to subvert the apoptotic machinery.

Pyroptosis is defined by the dependence on caspase-1 or caspase-11 in mice and either caspase-1 or caspase-4 in humans [30,44]. Caspase-1 activation is dependent on the formation of a macromolecular complex, termed the inflammasome. Numerous inputs and cellular stresses can trigger the formation of the inflammasome complex, often via the adaptor protein apoptosis associated speck-like protein containing a CARD (ASC), which bridges the interaction of the ‘sensing’ proteins [nucleotide-binding domain and leucine-rich repeat containing gene family (NLRs), retinoic acid-inducible gene 1 (RIG-1), absent in melanoma 2 (AIM2)] and caspase-1, leading to auto-cleavage and activation of caspase-1 [45]. Pyroptosis induces inflammation via the release of the active form of the pro-inflammatory cytokines interleukin (IL)-1α, IL-1β, and IL-18 [46] (Fig. 1). Necroptosis can induce inflammation and drive emergency hematopoiesis by releasing IL-1α, IL-33, and damage-associated host factors [47] (Fig. 1 and Fig. 2). Here, we will consider scenarios where these processes are subverted by pathogens and abnormalities in host biochemical pathways.

APOPTOSIS, NECROPTOSIS, AND PYROPTOSIS CROSS-TALK

An emerging theme in the field of inflammatory cell death is that the apoptotic and nonapoptotic cell death pathways communicate extensively. Vince et al.[48] demonstrate that when inhibitor of apoptosis proteins (IAPs) are depleted, RIPK3 activation triggers caspase-8 and NLRP3/caspase-1 activation, leading to reactive oxygen species production and IL-1β secretion independently of RIPK3 kinase activity and MLKL [49▪]. Interestingly, cIAPs were shown to regulate cytokine production and myelopoiesis in a RIPK1 and RIPK3-dependent manner that was independent of necroptosis [36▪▪].

Dimerization of RIPK1 and RIPK3 activates cell death; however, the precise pathway taken to cell death remains unclear. Evidence suggests that RIPK3 can drive MLKL-dependent necroptosis or caspase-1-dependent pyroptosis. Mutations affecting the kinase domain of RIPK3 unexpectedly induce caspase-8-dependent lethality, but not MLKL-mediated cell death [50▪]. Subsequent studies showed that the mutation likely induced a conformational change in RIPK3, exposing the receptor interacting protein homotypic interaction motif (RHIM) domain rather than inhibiting the kinase activity per se[51▪]. Cook et al.[52] propose that the availability of substrates, namely caspase-8, MLKL, and FADD, determine the outcome to RIPK1 and RIPK3 dimerization. A RIPK3 construct that can be induced to dimerize was used to show that the kinase domain of RIPK3 drives MLKL-mediated necroptosis in the absence of RIPK1, caspase-8, and FADD. In contrast, in the absence of MLKL, dimerized RIPK3 induces caspase-8-dependent apoptosis, and cleavage of caspase-3 and poly (ADP ribose) polymerase. This process is enhanced by RIPK1 and occurs independently of RIPK3 kinase function. These studies have revealed significant interactions between pyroptosis, necroptosis, and caspase-8-dependent apoptosis. How these interactions alter the morphological and biochemical changes associated with cell death, the kinetics of cell death, and the pathophysiological outcome of inflammatory cell death awaits further study.

CONTROVERSIAL KILLING BY MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN

MLKL has recently emerged as a central player in the execution of RIPK3-dependent necroptotic death, but its precise role in this cell death pathway is highly controversial [31]. Phosphorylation of the activation loop of MLKL induces a conformational change disrupting an auto-inhibitory interaction between the pseudokinase domain and the four-helix bundle. This promotes an interaction with phosphatidylinositol phosphates promoting membrane localization [53,54▪]. It is controversial whether this membrane localization and pore formation represents the end of this pathway [55], or if additional players such as phosphoglycerate mutase family member 5 (PGAM5), the mitochondrial fission factor Drp1, or the transient receptor potential melastatin-related 7 (TRPM7) exist downstream to induce mitochondrial fragmentation and calcium current across the plasma membrane to kill the cell [55–57]. Future in-vivo studies using cells deficient in these proteins in parallel with RIPK3-deficient cells will be helpful to determine the specific nature of RIPK3-dependent cell death.

INFLAMMATORY CELL DEATH DRIVES EMERGENCY HEMATOPOIESIS

The archetypal example of a nonapoptotic form of cell death driving emergency hematopoiesis comes from work on caspase-1 and IL-1β. IL-1β, the most commonly studied product of the pyroptotic cell death pathway, is a potent inducer of granulocyte colony-stimulating factor (G-CSF) and IL-6, both of which drive granulopoiesis [58] (Fig. 2). The other major cytokine processed by active caspase-1 – IL-18 [59] – can induce interferon (IFN)γ, which is known to regulate HSC self-renewal, repopulation, and proliferation during infection and aplastic anemia [60–62] (Fig. 2).

Interleukin-1α – a necroptotic [47] and pyroptotic DAMP [63] – can also influence G-CSF and IL-6 production to drive emergency hematopoiesis (Fig. 2). IL-33, which is an inflammatory DAMP released during necroptosis [34▪▪], can influence emergency hematopoiesis and eosinophil production. IL-33 can induce HSPC mobilization in a CCR2-dependent manner to fight fungal infection [64▪]. IL-33 also promotes IL-5 production and thereby can cause systemic eosinophilia in vivo[65] (Fig. 2). Eosinophils are now known to express cell surface receptors, paired immunoglobulin-like receptor (PIR)-A and PIR-B, which modulate eosinophil cell death activation to enable IL-5-mediated expansion, demonstrating the complexity of cell death pathways operating in discrete cell types during emergency hematopoiesis [66▪]. IL-33 also promotes the differentiation of bone marrow lineage-Sca1+ c-Kit-CD25+ cells to type 2 innate lymphoid cells (ILC2) [67]. The number of natural ILC2 (nILC2) also increases following IL-33 treatment in vivo, and these cells play key roles during Helminth infection [68▪].

NEGATIVE REGULATION OF EMERGENCY HEMATOPOIESIS BY INFLAMMATORY CELL DEATH

Two scenarios exist that can account for effects of nonapoptotic inflammatory cell death on emergency hematopoiesis: first, an indirect effect of chronic inflammation on HSPC activity; and secondly, direct killing of HSPCs (Fig. 2).

Indirect negative feedback of emergency hematopoiesis

Hematopoietic growth factors are induced to high levels during infection and they promote emergency hematopoiesis. Several inflammatory cytokines counteract the actions of hematopoietic growth factors to perturb hematopoiesis. Type I interferon drastically reduces the number of hematopoietic progenitor cells following lymphocytic choriomeningitis virus infection [5]. Its mechanism of action is not understood, but may act by licensing these cells to undergo nonapoptotic cell death [33▪▪,69–72,73▪,74] or they may interfere with the proliferation and differentiation of HSPCs [75]. IL-1β production during pyroptosis may interfere with emergency hematopoiesis because treatment of mice with recombinant IL-1 receptor antagonist supports hematopoiesis and reduces mortality following chemotherapy [76,77]. Consistently, G-CSF treatment increases the expression of the IL-1R antagonist and supports engraftment of donor HSC [78].

Another factor released from pyroptotic cells – IL-18 [59] – synergizes with IL-12 to up-regulate IFNγ which perturbs HSC proliferation, differentiation, and self-renewal at steady state, during infection with Mycobacterium avium or Ehrlichia muris[60,61], and when chronically expressed can lead to aplastic anemia [62] (Fig. 2). IFNγ pretreatment of HSPCs also reduces the engraftment potential of donor cells, suggesting that these are cell-intrinsic changes [79].

Damage-associated molecular patterns are released during pyroptosis and necroptosis, and they have diverse effects on hematopoiesis. For example, HMGB1 and mitochondrial DNA are potent inducers of type I interferon, and they have the capacity to negatively regulate emergency hematopoiesis [24,25,80]. IL-33, also considered a DAMP, can antagonize eosinophil production by inducing GM-CSF production, in contrast to its positive role in IL-5 production [65] (Fig. 2). Additional studies will be required to establish the physiological role of IL-33 in the regulation of eosinophil production via its effects on IL-5 and GM-CSF.

Direct negative feedback

Killing of HSPCs is hypothesized to be an efficient means of removing infected cells, thereby eliminating the risk of spread to progeny cells [30]. Both pyroptotic and necroptotic machinery exists in HSPCs, and both pathways have now been shown to have the capability to kill HSPCs. NLRP1-dependent caspase-1-dependent pyroptosis can kill HSPCs during hematopoietic stress induced by viral infection or chemotherapy, causing cytopenia, immunosuppression, and bone marrow failure [59] (Fig. 2). Recently, it was shown that deletion of caspase-1/11 improved the survival of neonatal mice following bacterial challenge. This reduction in mortality was associated with elevated numbers of HSC in the bone marrow and spleen [81▪▪]. Likewise, RIPK3-dependent necroptotic cell death limits the ‘self-renewal’ capacity of RIPK1-deficient long-term HSC in lethally-irradiated recipient mice in a tumor necrosis factor (TNF)-dependent process, suggesting that the necroptotic machinery can exert selective pressure on long-term HSC [34▪▪,82▪▪] (Fig. 2).

TARGETING CELL DEATH TO MODULATE EMERGENCY HEMATOPOIESIS

Pharmacological inhibition of pyroptosis and necroptosis may have therapeutic value in diverse clinical settings including infection, auto-immunity, and hematopoietic stress. For example, an NLRP3-specific inhibitor has been shown to protect against experimental autoimmune encephalomyelitis and murine neonatal lethality caused by mutations equivalent to human cryopyrin-associated periodic syndrome [83]. Caspase-1 and caspase-4 inhibitors have not been tested in the clinic in the setting of infection, but extensive mouse data suggest that inhibitors will be beneficial for patients with systemic inflammatory disease and infection-triggered cytopenias [59,81▪▪,84,85].

Genetic or pharmacological inhibition of the necroptotic machinery, namely RIPK1 and RIPK3, alleviates cerulean-induced pancreatitis [86,87], TNF-induced inflammation in mice [35,50▪,88,89], atherosclerosis in Apoe and Ldlr mutant mice [90], retinal degeneration [91,92], ischemia-reperfusion injury of the kidneys [93,94], myocardial infarction [95], steatohepatitis, and hepatic injury induced by ethanol [96–98]. Furthermore, necroptosis was first described to play a role in viral defense during VACV infection, a virus that can inhibit apoptosis [99,100] and pyroptosis [101]. Chan et al.[102] showed that RIPK1 was required for TNF-induced necroptosis of VACV-infected cells. Subsequently, VACV-induced necroptosis was shown to require RIPK3 [103]. Treatment with the RIPK1 inhibitor, Nec-1, or the human MLKL inhibitor, NSA, inhibits the cytopathic effects of the HIV-1 virus [104]. HSV-1 and HSV-2 induce a RIPK3/MLKL-dependent death of mouse embryonic fibroblasts, and RIPK3-deficient mice are susceptible to HSV-1 and display high viral titers [105,106]. In contrast, work in human cell lines demonstrates that the ICP6 and ICP10 proteins from HSV-1 and HSV-2, respectively, can inhibit TNF-induced necroptosis, indicating cell type and possibly species-specific differences in necroptosis pathways [106,107]. Exacerbations in necroptosis and pyroptosis have therefore been demonstrated in a variety of mouse models, but their contribution to human disease is only now being tested in clinical trials for chronic inflammatory disease.

The lethality caused by loss of RIPK1 and the normal development of RIPK3-deficient mice suggested that RIPK3 would be ideal for drug development. However, mice with a RIPK3 D161N mutation display increased caspase-8 and RIPK1 activity leading to apoptosis. Compounds targeting the kinase activity of RIPK3 can at high concentrations also induce apoptosis by promoting a conformational change in RIPK3 that drives RHIM interactions with RIPK1 and activation of caspase-8 [51▪]. Mutations of other residues of RIPK3 (D161G, D143N, K51A) inhibit necroptosis in response to TLR3, TLR4, TNFR1, DAI, and IFNβ, but do not trigger the lethality seen in the RIPK3 D161N mutants [51▪]. These data suggest that RIPK3 antagonists may be valuable for inhibition of necroptosis, but are likely to promote induction of apoptosis in some settings, a feature that may be useful in the setting of cancer chemotherapy.

CONCLUSION

As we now appreciate the complex interplay between the nonapoptotic and apoptotic cell death cascades, and the appearance of discrete features of apoptosis in response to nonapoptotic stimuli, more rigorous genetic, biochemical, and morphological information will be required to characterize, refine, and integrate the many forms of cell death that are now known to exist. Characterization of additional DAMPs generated during nonapoptotic cell death will shed light on the indirect modulators of emergency hematopoiesis. Recent findings have also unveiled nonapoptotic cell death as a key biological process restricting HSPC ‘self-renewal’, and could have clinical implications in the setting of systemic infection, and also for improving the engraftment potential of HSPC in transplantation settings using bone marrow, G-CSF-mobilized peripheral blood stem cells, umbilical cord blood units, and for gene therapy clinical trials.

Acknowledgements

None.

Financial support and sponsorship

The study was supported by NIH grant 1R01HL124209–01A1 (B.A.C.), and J.S. has an NHMRC fellowship (541901).

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest

REFERENCES

1. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44:287–299.
2. Bradley TR, Robinson W, Metcalf D. Colony production in vitro by normal polycythaemic and anaemic bone marrow. Nature 1967; 214:511.
3. Venet F, Davin F, Guignant C, et al. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 2010; 34:358–363.
4. Hall MW, Geyer SM, Guo CY, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med 2013; 41:224–236.
5. Binder D, Fehr J, Hengartner H, Zinkernagel RM. Virus-induced transient bone marrow aplasia: major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp Med 1997; 185:517–530.
6. Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010; 16:446–451.
7. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J Virol 1999; 73:4806–4812.
8. Slobedman B, Stern JL, Cunningham AL, et al. Impact of human cytomegalovirus latent infection on myeloid progenitor cell gene expression. J Virol 2004; 78:4054–4062.
9. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A 1994; 91:11879–11883.
10. Minton EJ, Tysoe C, Sinclair JH, Sissons JG. Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow. J Virol 1994; 68:4017–4021.
11. Nixon CC, Vatakis DN, Reichelderfer SN, et al. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 2013; 122:2195–2204.
12. Mandle T, Einsele H, Schaller M, et al. Infection of human CD34+ progenitor cells with Bartonella henselae results in intraerythrocytic presence of B. henselae. Blood 2005; 106:1215–1222.
13. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014; 505:509–514.
14. Monroe KM, Yang Z, Johnson JR, et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 2014; 343:428–432.
15. Zauli G, Vitale M, Re MC, et al. In vitro exposure to human immunodeficiency virus type 1 induces apoptotic cell death of the factor-dependent TF-1 hematopoietic cell line. Blood 1994; 83:167–175.
16. Banda NK, Tomczak JA, Shpall EJ, et al. HIV-gp120 induced cell death in hematopoietic progenitor CD34+ cells. Apoptosis 1997; 2:61–68.
17. Aillet F, Masutani H, Elbim C, et al. Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines. J Virol 1998; 72:9698–9705.
18. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 1999; 96:14541–14546.
19. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166:6952–6963.
20▪. Sun J, Ramos A, Chapman B, et al. Clonal dynamics of native haematopoiesis. Nature 2014; 514:322–327.

This study suggests that long-lived hematopoietic progenitor cells supply demand for immune cells throughout life, and that depletion of this population will impact emergency hematopoiesis.

21▪. Busch K, Klapproth K, Barile M, et al. Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. Nature 2015; 518:542–546.

This study suggests that ST-HSC and MPP supply the majority of demand for immune cell production but that long-term HSC are still ultimately responsible for maintaining life-long hematopoiesis and immunity.

22. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239–257.
23. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335:440–442.
24. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104–107.
25. Yanai H, Ban T, Wang Z, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009; 462:99–103.
26▪▪. Li Y, Esain V, Teng L, et al. Inflammatory signaling regulates embryonic hematopoietic stem and progenitor cell production. Genes Dev 2014; 28:2597–2612.

A study suggesting that sterile DAMPs cause inflammation and thereby influence hematopoiesis.

27. Schuettpelz LG, Link DC. Regulation of hematopoietic stem cell activity by inflammation. Front Immunol 2013; 4:204.
28. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 2007; 7:964–974.
29▪. Galluzzi L, Bravo-San Pedro JM, Vitale I, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015; 22:58–73.

Criteria for classifying different forms of cell death.

30. Croker BA, O’Donnell JA, Gerlic M. Pyroptotic death storms and cytopenia. Curr Opin Immunol 2014; 26:128–137.
31. Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148:213–227.
32▪▪. Dillon CP, Weinlich R, Rodriguez DA, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 2014; 157:1189–1202.

RIPK1 negatively regulates caspase-8-mediated apoptosis and RIPK3-dependent necroptosis, thereby preventing DAMP release and inflammation.

33▪▪. Kaiser WJ, Daley-Bauer LP, Thapa RJ, et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc Natl Acad Sci U S A 2014; 111:7753–7758.

RIPK1 negatively regulates caspase-8-mediated apoptosis and RIPK3-dependent necroptosis, thereby preventing DAMP release and inflammation.

34▪▪. Rickard JA, O’Donnell JA, Evans JM, et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 2014; 157:1175–1188.

RIPK1 negatively regulates caspase-8-mediated apoptosis and RIPK3-dependent necroptosis, thereby preventing DAMP release and inflammation and further showing the importance of this regulation in HSPC following transplantation.

35. Takahashi N, Duprez L, Grootjans S, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3:e437.
36▪▪. Wong WW, Vince JE, Lalaoui N, et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood 2014; 123:2562–2572.

A study showing that cIAPs regulate myelopoiesis by impairing RIPK3-dependent cytokine production prior to necroptosis.

37. Kaiser WJ, Sridharan H, Huang C, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 2013; 288:31268–31279.
38. Upton JW, Kaiser WJ, Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 2012; 11:290–297.
39. Stanger BZ, Leder P, Lee TH, et al. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995; 81:513–523.
40. Oberst A, Dillon CP, Weinlich R, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471:363–367.
41▪. Dannappel M, Vlantis K, Kumari S, et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513:90–94.

This study confirms that RIPK1 negatively regulates caspase-8-mediated apoptosis and RIPK3-dependent necroptosis using conditional knockouts.

42. Zhang H, Zhou X, McQuade T, et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011; 471:373–376.
43. Kaiser WJ, Upton JW, Long AB, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011; 471:368–372.
44. Shi J, Zhao Y, Wang Y, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 2014; 514:187–192.
45. Proell M, Gerlic M, Mace PD, et al. The CARD plays a critical role in ASC foci formation and inflammasome signalling. Biochem J 2013; 449:613–621.
46. Bauernfeind F, Hornung V. Of inflammasomes and pathogens: sensing of microbes by the inflammasome. EMBO Mol Med 2013; 5:814–826.
47. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013; 38:209–223.
48. Vince JE, Wong WW, Gentle I, et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 2012; 36:215–227.
49▪. Lawlor KE, Khan N, Mildenhall A, et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat Commun 2015; 6:6282.

This research shows extensive cross-talk between the necroptotic and pyroptotic pathways.

50▪. Newton K, Dugger DL, Wickliffe KE, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343:1357–1360.

One of the two studies to show that RIPK3 can signal to caspase-8.

51▪. Mandal P, Berger SB, Pillay S, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014; 56:481–495.

One of the two studies to show that RIPK3 can signal to caspase-8.

52. Cook WD, Moujalled DM, Ralph TJ, et al. RIPK1- and RIPK3-induced cell death mode is determined by target availability. Cell Death Differ 2014; 21:1600–1612.
53. Hildebrand JM, Tanzer MC, Lucet IS, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci U S A 2014; 111:15072–15077.
54▪. Dondelinger Y, Declercq W, Montessuit S, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 2014; 7:971–981.

A study supporting a direct role for MLKL in pore formation and cell lysis.

55. Cai Z, Jitkaew S, Zhao J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2014; 16:55–65.
56. Wang Z, Jiang H, Chen S, et al. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 2012; 148:228–243.
57. Moujalled DM, Cook WD, Murphy JM, Vaux DL. Necroptosis induced by RIPK3 requires MLKL but not Drp1. Cell Death Dis 2014; 5:e1086.
58. Dubois CM, Neta R, Keller JR, et al. Hematopoietic growth factors and glucocorticoids synergize to mimic the effects of IL-1 on granulocyte differentiation and IL-1 receptor induction on bone marrow cells in vivo. Exp Hematol 1993; 21:303–310.
59. Masters SL, Gerlic M, Metcalf D, et al. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 2012; 37:1009–1023.
60. Baldridge MT, King KY, Boles NC, et al. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature 2010; 465:793–797.
61. MacNamara KC, Jones M, Martin O, Winslow GM. Transient activation of hematopoietic stem and progenitor cells by IFNgamma during acute bacterial infection. PLoS One 2011; 6:e28669.
62. Lin FC, Karwan M, Saleh B, et al. IFN-gamma causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation. Blood 2014; 124:3699–3708.
63. Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388–400.
64▪. Kim J, Kim W, Le HT, et al. IL-33-induced hematopoietic stem and progenitor cell mobilization depends upon CCR2. J Immunol 2014; 193:3792–3802.

A study showing IL-33 can promote HSPC mobilization.

65. Dyer KD, Percopo CM, Rosenberg HF. IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo. Immunol Lett 2013; 150:41–47.
66▪. Ben Baruch-Morgenstern N, Shik D, Moshkovits I, et al. Paired immunoglobulin-like receptor A is an intrinsic, self-limiting suppressor of IL-5-induced eosinophil development. Nat Immunol 2014; 15:36–44.

This study reveals that eosinophils express a constitutively active kill switch that needs to be suppressed to allow for full expansion in response to IL-5.

67. Brickshawana A, Shapiro VS, Kita H, Pease LR. Lineage(-)Sca1+c-Kit(-)CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J Immunol 2011; 187:5795–5804.
68▪. Huang Y, Guo L, Qiu J, et al. IL-25-responsive, lineage-negative KLRG1(hi) cells are multipotential ’inflammatory’ type 2 innate lymphoid cells. Nat Immunol 2015; 16:161–169.

A novel immune effector cell that differentiates in response to IL-33, a necroptotic DAMP.

69. Thapa RJ, Nogusa S, Chen P, et al. Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc Natl Acad Sci U S A 2013; 110:E3109–E3118.
70. McComb S, Cessford E, Alturki NA, et al. Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages. Proc Natl Acad Sci U S A 2014; 111:E3206–E3213.
71. Rathinam VA, Vanaja SK, Waggoner L, et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 2012; 150:606–619.
72. Case CL, Kohler LJ, Lima JB, et al. Caspase-11 stimulates rapid flagellin-independent pyroptosis in response to Legionella pneumophila. Proc Natl Acad Sci U S A 2013; 110:1851–1856.
73▪. Meunier E, Dick MS, Dreier RF, et al. Caspase-11 activation requires lysis of pathogen-containing vacuoles by IFN-induced GTPases. Nature 2014; 509:366–370.

A study indicating that caspase-11 responds to intracellular Gram-negative bacteria to induce pyroptosis.

74. Pilla DM, Hagar JA, Haldar AK, et al. Guanylate binding proteins promote caspase-11-dependent pyroptosis in response to cytoplasmic LPS. Proc Natl Acad Sci U S A 2014; 111:6046–6051.
75. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458:904–908.
76. Qian L, Xiang D, Zhang J, et al. Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo. Biomed Pharmacother 2013; 67:108–115.
77. Zhang J, Xiang D, Zhu S, et al. Interleukin 1 receptor antagonist inhibits normal hematopoiesis and reduces lethality and bone marrow toxicity of 5-fluouracil in mouse. Biomed Pharmacother 2009; 63:501–508.
78. Schwabe M, Hartert AM, Bertz H, Finke J. Treatment with granulocyte colony-stimulating factor increases interleukin-1 receptor antagonist levels during engraftment following allogeneic stem-cell transplantation. Eur J Clin Invest 2004; 34:759–765.
79. Yang L, Dybedal I, Bryder D, et al. IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells. J Immunol 2005; 174:752–757.
80. White MJ, McArthur K, Metcalf D, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 2014; 159:1549–1562.
81▪▪. Gentile LF, Cuenca AL, Cuenca AG, et al. Improved emergency myelopoiesis and survival in neonatal sepsis by caspase-1/11 ablation. Immunology 2015; [Epub ahead of print].

A study examining the correlation between caspase1/11-deficiency, hematopoiesis and mortality. This supports the clinical administration of caspase-1 inhibitors.

82▪▪. Roderick JE, Hermance N, Zelic M, et al. Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis. Proc Natl Acad Sci U S A 2014; 111:14436–14441.

This study confirms that loss of RIPK1 induces bone marrow failure due to apoptosis and necroptosis of HSPCs using conditional knockouts.

83. Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21:248–255.
84. Brydges SD, Mueller JL, McGeough MD, et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 2009; 30:875–887.
85. Meng G, Zhang F, Fuss I, et al. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 2009; 30:860–874.
86. He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137:1100–1111.
87. Wu J, Huang Z, Ren J, et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res 2013; 23:994–1006.
88. Linkermann A, Brasen JH, De Zen F, et al. Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor-alpha-induced shock. Mol Med 2012; 18:577–586.
89. Duprez L, Takahashi N, Van Hauwermeiren F, et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 2011; 35:908–918.
90. Lin J, Li H, Yang M, et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep 2013; 3:200–210.
91. Murakami Y, Matsumoto H, Roh M, et al. Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsRNA-induced retinal degeneration. Cell Death Differ 2014; 21:270–277.
92. Trichonas G, Murakami Y, Thanos A, et al. Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis. Proc Natl Acad Sci U S A 2010; 107:21695–21700.
93. Linkermann A, Brasen JH, Himmerkus N, et al. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int 2012; 81:751–761.
94. Lau A, Wang S, Jiang J, et al. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am J Transplant 2013; 13:2805–2818.
95. Oerlemans MI, Liu J, Arslan F, et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol 2012; 107:270.
96. Roychowdhury S, Chiang DJ, Mandal P, et al. Inhibition of apoptosis protects mice from ethanol-mediated acceleration of early markers of CCl4-induced fibrosis but not steatosis or inflammation. Alcohol Clin Exp Res 2012; 36:1139–1147.
97. Roychowdhury S, McMullen MR, Pisano SG, et al. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 2013; 57:1773–1783.
98. Vucur M, Reisinger F, Gautheron J, et al. RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. Cell Rep 2013; 4:776–790.
99. Dobbelstein M, Shenk T. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J Virol 1996; 70:6479–6485.
100. Wasilenko ST, Stewart TL, Meyers AF, Barry M. Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc Natl Acad Sci U S A 2003; 100:14345–14350.
101. Gerlic M, Faustin B, Postigo A, et al. Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation. Proc Natl Acad Sci U S A 2013; 110:7808–7813.
102. Chan FK, Shisler J, Bixby JG, et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem 2003; 278:51613–51621.
103. Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137:1112–1123.
104. Pan T, Wu S, He X, et al. Necroptosis takes place in human immunodeficiency virus type-1 (HIV-1)-infected CD4+ T lymphocytes. PLoS One 2014; 9:e93944.
105. Wang X, Li Y, Liu S, et al. Direct activation of RIP3/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense. Proc Natl Acad Sci U S A 2014; 111:15438–15443.
106. Huang Z, Wu SQ, Liang Y, et al. RIP1/RIP3 binding to HSV-1 ICP6 initiates necroptosis to restrict virus propagation in mice. Cell Host Microbe 2015; 17:229–242.
107. Guo H, Omoto S, Harris PA, et al. Herpes simplex virus suppresses necroptosis in human cells. Cell Host Microbe 2015; 17:243–251.
Keywords:

emergency hematopoiesis; hematopoietic stem and progenitor cells; inflammation; necroptosis; pyroptosis

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.